• P. N. Patsalos


Pregabalin (Fig. 1) corresponds chemically to S-3-(aminomethyl)-5-methylhexanoic acid with an empirical formula of C8H17NO2 and a molecular weight of 159.2.


Valproic Acid Oral Ingestion Empirical Formula Therapeutic Drug Monitoring Renal Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 (Suppl 6):13–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother. 2004;13:1–168.Google Scholar
  4. 4.
    May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29:789–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Bockbrader HN, Burger PJ, Corrigan BW, Kugler AR, Knapp LE, Garofalo EA, Lalonde RL. Population pharmacokinetic (PK) analysis of commonly prescribed antiepileptic drugs (AEDs) co-administered with pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia. 2001;42 (Suppl 7):84.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations